Related Experiment Video
Updated: Jul 2, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Glucose control in the UKPDS: what did we learn?
1Diabetes and Metabolism, Division of Medicine, University of Bristol, Bristol, UK. Edwin.Gale@bristol.ac.uk
Diabetic Medicine : a Journal of the British Diabetic Association
|September 9, 2008
Summary
Aggressively managing blood glucose in Type 2 diabetes is crucial. The UK Prospective Diabetes Study (UKPDS) revealed that reducing vascular risk requires multifaceted approaches beyond just glucose control.
Area of Science:
- Endocrinology
- Clinical Trials
- Diabetes Research
Background:
- The UK Prospective Diabetes Study (UKPDS) investigated the impact of improved glucose control on diabetes complications.
- It aimed to compare different treatment modalities: diet, oral agents, and insulin.
Purpose of the Study:
- To determine if tighter glucose control reduces macrovascular and microvascular complications in diabetes.
- To assess the comparative effectiveness of various interventions for achieving glucose control.
Main Methods:
- The UKPDS employed a flexible trial design, allowing for adaptive interventions and analyses.
- It involved a long-term prospective cohort study with multiple randomized controlled trials.
Main Results:
- Aggressive glucose control is essential for managing Type 2 diabetes.
- Treatment strategies must adapt to the progression of pancreatic beta-cell failure.
- Reducing vascular risk is the primary therapeutic goal, utilizing all available means.
Conclusions:
- The UKPDS highlighted the necessity of proactive and intensified glucose management.
- It underscored that comprehensive vascular risk reduction is paramount in diabetes care.
- The study's flexible design facilitated key insights into diabetes treatment evolution.
Related Concept Videos
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...